Document:

Fufaiting Financing Contract

 

(Contract No. 2012DY-F1205)

 

(This is a Summary Translation for Reference
Only)

 

Party A:           
Inner Mongolia Yongye Nongfeng Biotechnology Co., Ltd.

Legal Representative:

 

Party B:           
CITIC Bank Corporation Limited (CITIC), Hohhot Branch 

	Legal Representative:	SUN Xiaofan

 

	Place of Execution:	Hohhot Branch
	Date of Execution:	December 5, 2012

 

Party A applies to Party B for financing
by selling in the Fufaiting method Party A’s accounts receivable from its export business and Party B accepts Party A’s
application. The two parties have entered into the following contract in accordance with the applicable law and statutes.

 

Article I            Definition

 

1.        “Fufaiting”
means the financing activity provided by Party B by buying out with the waiver of recourse the long-term promissory bills and long-term
debts guaranteed or confirmed by bank letter of credit/acceptance notes obtained legitimately by Party A from its export business,
long-term promissory bills issued by Party A guaranteed by an importer’s bank, or long-term promissory bills issued by an
importer.

 

2.        “Buy-out
target” means accounts receivable represented in the form of certain notes and invoices and all the associated rights, including
but not limited to right to demand payment, guarantee interest, recourse against a third party but excluding Party A’s responsibilities
and obligations under any trade contracts with regard to any person and/or relevant third party.

 

3.        “Term
of the buy-out” means the period from the day of Party B’s buy-out of such debts to the due date of the bank letter
of credit/acceptance note or other predetermined due date, or to the due date of the bank letter of credit/acceptance note from
an importer’s bank, plus at least a 3-day grace period.

 

4.        “Buy-out
net amount” means the amount of the face value of the debt claims minus the buy-out interest.

 

    	1

    	 

    

 

Article II           Notes
and Invoices That Party A Must Provide

 

At the time of transferring the debt claims
underlying the long-term letters of credit by Party A to Party B, Party A must provide the following to Party B:

 

1.        Copies
of letters of credit and their amendments (if any);

 

2.        Copies
of all the notes and invoices underlying such letters of credit;

 

3.        The
original copies of the bank promissory notes or acceptance bills;

 

4.        Other
documents requested by Party B.

 

If the debt claims transferred by Party
A are not under any letters of credit (including but not limited to bank promissory notes or acceptance bills), Party A must provide
to Party B the following notes and invoices:

 

1.        Original
bank promissory notes or acceptance bills with words “guarantee” or “acceptance” and seals from the issuing
bank;

 

2.       Original
letters of credit and their amendments (if any) and confirmation letters/telegraphs from the issuing bank agreeing to the transfer
of the rights underlying such letters of credit;

 

3.        Copies
of all notes and invoices underlying bank promissory notes or acceptance bills;

 

4.        Other
documents requested by Party B.           

 

Article III          Business
Procedures

 

During the effective period of this contract,
Party A must submit a “Fufaiting Financing Application” to Party B for each Fufaiting service. Such application will
be the irrevocable offer from Party A and will be the component part of this contract. Upon approval, Party B will deposit the
buy-out net amount to following Party A’s account:

 

Bank:    CITIC Bank Corporation Limited (CITIC), Hohhot
Branch

 

Account Number:           7271310182200023199

 

Article IV          Calculation
of the Buy-out Net Amount

 

The two parties agree that the calculation
method for the buy-out net amount is:

 

    	2

    	 

    

 

Fufaiting buy-out net amount = face value
of the debt claims – buy-out interest – relevant fees;

 

Buy-out interest = face value of the debt
claims x term of the buy-out (number of days) x buy-out rate/360;

 

Buy-out rate = LIBOR + risk rate (risk rate
is to be determined by the country rating of the importing country and the credit assessment of the letters of credit issuing bank);

 

Grace period is the number of days between
the due dates of the accounts receivable and the actual dates when Party B receives payments.

 

Relevant fees mean expenses involved in
settlements.

 

Article V           Party
A’s Representations and Warranties

 

1.        When
applying for Fufaiting service hereunder, Party A must promptly provide to Party B the letters of credit and bank promissory notes
or acceptance bills mentioned in Article II. Party B has the right to refuse to handle the Fufaiting service if the bank promissory
notes or acceptance bills do not meet Party B’s requirements.

 

2.        The
bank promissory notes or acceptance bills mentioned in Article II submitted are authentic and valid and meet the international
standards or customs, the state’s relevant regulations and Party B’s requirements.

 

3.        Party
A has the complete rights to the debt claims transferred to Party B in accordance with the provisions herein, there are no defects
on such rights, and such rights have not been transferred either in part or in whole to any third party.

 

4.        The
transfer of the claims hereunder is complete transfer and Party B will have the complete rights to such claims.

 

5.        The
background of trades involved in this contract is true and legitimate and there is no situation where there are fraud or any trade
in violation of law, any stop orders from any bank or judicial organization, thus causing Party A to be unable to recover such
debt claims.

 

6.        All
the conditions (buy-out net amount, buy-out rate and term as determined by Party B) governing such buy-out are to be based on those
set forth in the review section of the “Fufaiting Financing Application,” and Party A completely accept such conditions.

 

7.        Party
A transfers completely and legally the debt claims hereunder to Party A; however such transfer will not cause Party B to be responsible
for any of Party A’s obligations under any specific trade contract, and Party A is still responsible for any such obligations.

 

    	3

    	 

    

 

8.        After
obtaining financing, if Party A receives any payment applicable to the accounts receivable hereunder, Party A must notify Party
B immediately and hand over such payment to Party B.

 

9.        Party
A must assist Party B at Party B’s request in collecting payments for such accounts receivable.

 

Article VI          Waiver
of Recourse and Exceptions

 

After Party B has processed the Fufaiting
service applied for by Party A, Party B will obtain the notes and invoices corresponding to the debt claims and Party B will waive
recourse against Party A except under the following circumstances:

 

1.        The
notes and invoices involving the trades are not authentic or are in violation of laws, statutes and regulations;

 

2.        The
notes and invoices corresponding to the debt claims transferred hereunder are fraudulent;

 

3.        Party
A violates the representations and warranties made in Article V herein or other provisions stipulated herein;

 

4.        There
are stop-payment orders placed by any court on the letters of credit corresponding to the notes and invoices regarding the debt
claims;

 

5.        Party
A willfully, or Party A’s negligence, causes any defects to the effectiveness of this contract or obstructs Party B’s
exercise of any rights transferred.

 

Upon the occurrence of any of the above,
Party B shall have the right to demand that Party A return all the amount that Party B has paid to Party A and assume responsibility
for all losses suffered by Party B. In addition, Party B shall have the right to charge Party A a default penalty at the following
rate starting from the date of the buy-out until the full repayment of all the buy-out amount:

 

(1)      At
the daily rate of 0.05% on the buy-out net amount;

 

(2)      (N/A)

 

(3)      (N/A)

 

Upon the occurrence of the above, Party
B shall have the right to deduct the relevant amount directly from Party A’s account with Party B or to pursue Party A by
other means.

 

If Party A’s breach causes Party B
to resort to litigation, arbitration or other means to realize its claims, Party A must be responsible for the collection fees,
litigation fees (or arbitration fees), insurance fees, public announcement fees, enforcement fees, attorney fees, travel and lodging
expenses and other fees incurred by Party B.

 

    	4

    	 

    

 

Article VII         Other
Matters

 

1.        All the “Fufaiting Financing Applications”
hereunder are the inseparable parts of this contract.

 

Article VIII       Governing
Law

 

This contract is governed by the law of
the People’s Republic of China

 

Article IX         Resolution
of Dispute

 

All disputes arising from this contract
must be resolved through consultation between the two parties; if such consultation fails, either party may submit such disputes
to the court at Party B’s location for resolution.

 

Article X           Effectuation,
Modification and Dissolution

 

This agreement shall become effective upon
execution by the respective representatives of the parties hereto;

 

After this contract has become effective,
neither party can make modify or dissolve it without the other party’s approval; if the contract does need to be modified
or dissolved, written notice must be given at least 30 days in advance and the parties hereto must enter into written agreement
regarding its dissolution.

 

Article XI         This
contract is in duplicates with one to each party.

 

	Party A:	(Seal or Special Business Seal)
	 	/seal/   Inner Mongolia Yongye Nongfeng Biotechnology Co., Ltd.

Legal Representative:   /s/ ZHAO Shijun

 

	Party B:	(Seal or Special Business Seal)
	 	/seal/ CITIC Bank Corporation Limited (CITIC), Hohhot Branch,

Legal Representative:   /s/ SUN Xiaofan

 

    	5EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT
(the “Agreement”) is made and entered into this 25th day of March, 2013 but effective as of the 26th
day of March, 2013 (the “Effective Date”) by and between Repros Therapeutics Inc., a Delaware corporation (the
“Company”), and Jaye Thompson, PhD (the “Employee”).

 

WITNESSETH

 

WHEREAS, the Company
desires to employ the Employee as its Senior Vice President of Clinical and Regulatory on the terms and subject to the conditions
set forth herein, and the Employee desires to accept such employment.

 

NOW, THEREFORE, in
consideration of the mutual covenants, promises and agreements contained herein, and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

		1.	Employment.

 

(a)               
The Company hereby employs the Employee and the Employee hereby accepts employment as the Senior Vice President of
Clinical and Regulatory of the Company, subject to the direction of the Chief Executive Officer and the Board of Directors of the
Company. Employee agrees that she shall perform and discharge well and faithfully the duties and responsibilities that are assigned
to her by the Chief Executive Officer and the Board of Directors of the Company, which shall include, but are not limited
to: (i) overseeing the clinical development activities of the Company relating to the Company’s two product candidates, Proellex®
and Androxal®; (ii) assisting the CEO in developing comprehensive management strategies for the Company; (iii) assisting
the CEO in the general management of the Company's operations; and (iv) performing such other duties as may be reasonably assigned
to Employee from time to time. The Employee agrees to devote such of her time, attention and energy to the business of the Company,
and any of its subsidiaries or affiliates, as may be required to perform the duties and responsibilities assigned to her by the
Chief Executive Officer and the Board of Directors of the Company to the best of her ability and with requisite diligence.

 

(b)              
The Employee agrees to comply in all material respects, at all times during the Term (as defined in Section 2
hereof), with all applicable policies, rules and regulations of the Company.

 

2.             Term. Subject to the terms hereof, this Agreement shall commence on the Effective Date hereof and shall
terminate on the first anniversary of the Effective Date (the “Initial Term”); provided, that this Agreement
will automatically renew for successive one-year periods after the Initial Term (each an “Additional Term”)
unless terminated in accordance with Section 6. The Initial Term together with any Additional Term shall be referred to herein
as the “Term.”

 

    	 

    	 

    

 

		3.	Compensation.

 

(a)               
The Company agrees to pay to Employee during the Initial Term a base annual salary of $250,000, payable in equal
semi-monthly installments or on any other periodic basis consistent with the Company's payroll procedures, subject only to such
payroll and withholding deductions as are required by applicable federal and state laws. The base annual salary for each Additional
Term shall be reviewed on an annual basis by the Board of Directors and recommendations for a salary adjustment shall be made based
on both individual and corporate performance; provided, however, that there is no assurance that the base annual salary
will be increased for any subsequent Additional Term, such decision to be within the discretion of the Board of Directors.

 

(b)              
The Company will issue, to Employee, an incentive stock option (the “Option”) to purchase 100,000
shares of the Company’s Common Stock under the Company’s Stock Option Plan, at an exercise price equal to the closing
price of the Company’s Common Stock on the Nasdaq Capital Market on the Effective Date, subject to commencement of employment.
Such shares shall vest and be exercisable at a rate of 1/12th of the total thereof for each quarter of Employee’s
employment following the Effective Date, provided that all shares shall vest and be exercisable in the event of a Change of Control
(as defined below).

 

(c)               
The Employee shall be eligible to receive an annual bonus, in amounts to be determined from time to time by the Board
of Directors of the Company provided, however, that there is no assurance that the Employee will be paid a bonus for each
given year.

 

		4.	Fringe Benefits; Expenses.

 

(a)               
So long as the Employee is employed by the Company, the Employee shall participate in all employee benefit plans
sponsored by the Company for its executive employees, including, but not limited to, vacation policy, health insurance, dental
insurance and retirement plans; provided, however, that the nature, amount and limitations of such plans shall be
determined from time to time by the Board of Directors of the Company.

 

(b)              
The Company agrees to reimburse the Employee for all reasonable out-of-pocket expenses incurred by her in the performance
of her duties, subject to the submission of appropriate documentation in accordance with the Company's expense reimbursement policy
as in existence from time to time.

 

5.             Confidential
Information and Non-Competition. The Employee has executed and agrees to comply with the Confidentiality, Proprietary
Information and Inventions and Non-Competition Agreement, a copy of which is attached as Exhibit A hereto and incorporated
herein by reference.

 

    	 

    	 

    

 

		6.	Termination.

 

(a)               
At any time during the Term, the Company may, at its sole discretion, discharge the Employee, with or without “Cause”.
Such termination shall be effective on delivery of written notice to the Employee of the Company's election to terminate this Agreement
under this Section 6. For purposes of this Agreement, the following events shall constitute “Cause”: (i) the
conviction of the Employee by a court of competent jurisdiction of a crime involving moral turpitude; (ii) the commission,
or attempted commission, by the Employee of an act of fraud on the Company; (iii) the misappropriation, or attempted misappropriation,
by the Employee of any funds or property of the Company; (iv) the continued and unreasonable failure by the Employee to perform
in any material respect her obligations under the terms of this Agreement; (v) the knowing engagement by the Employee, without
the written approval of the Board of Directors, in any direct, material conflict of interest with the Company without compliance
with the Company's conflict of interest policy; (vi) the knowing engagement by the Employee, without the written approval
of the Board of Directors, in any activity which competes with the business of the Company or which would result in a material
injury to the Company; or (vii) the knowing engagement by the Employee in any activity that would constitute a material violation
of the provisions of the Company's Insider Trading Policy or Business Ethics Policy, if any, then in effect.

 

If the Company terminates the
Employee's employment under this Agreement for reasons other than Cause or if Employee terminates her employment for Good Reason
(as defined below), then the Company shall, subject to the terms of this Section 6, pay to the Employee (or her estate or
representative, as appropriate) an amount equal to six (6) months compensation at her then current salary, payable semi-monthly
or in accordance with the Company's payroll procedures, and shall continue to provide benefits in the kind and amounts provided
up through the date of termination for the six (6) month period, including, without limitation, continuation of any Company-paid
benefits as described in Section 4 of this Agreement for the Employee and her family. Under no circumstances shall the Employee
be entitled to any compensation or continuation of benefits for any period of time following her termination if her termination
is for Cause. If the Company terminates the Employee's employment under this Agreement for reasons other than Cause, the Employee
agrees to accept, in full settlement of any and all claims, losses, damages and other demands that the Employee may have arising
out of such termination as liquidated damages and not as a penalty, the six (6) month salary payments and continuation of Company-paid
benefits as set forth above. The Employee hereby waives any and all rights that she may have to bring any cause of action or proceeding,
as a result of such termination, except to enforce the Company's obligation to pay amounts owing pursuant to this Section 6.

 

(b)              
This Agreement will terminate automatically on the earliest to occur of: (i) the death or disability of the
Employee; or (ii) the voluntary retirement of the Employee.

 

    	 

    	 

    

 

(c)               
If at any time during the Term of this Agreement, the Employee is unable to perform effectively her duties hereunder
because of physical or mental disability, the Company shall continue payment of compensation as provided in Section 3 hereof
during the first twelve (12) month period of such disability to the extent not covered by the Company's disability insurance policies,
if any. On the expiration of such twelve (12) month period, the Company, at its sole discretion, may continue payment of the Employee's
salary for such additional periods as the Company elects or may terminate this Agreement without any further obligations thereunder.
If the Employee should die during the Term of this Agreement, the Employee's employment and the Company's obligations hereunder
shall terminate as of the last day of the month in which the Employee's death occurs.

 

(d)              
As used in this Agreement, “Good Reason” shall mean: (i) any material diminution in the title,
powers, duties, responsibilities or functions of the Employee as described in Section 1 above; (ii) any unilateral reduction of
Employee’s salary unless such reduction is applicable to all executive officers on a similar basis; or (iii) movement of
the Employee’s principal place of employment greater than fifty (50) miles from its current location.

 

As used in this Agreement, a
“Change of Control” shall mean:

 

(i)the
acquisition after the Effective Date by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of
the Securities Exchange Act of 1934, as amended) (a “Person”) of beneficial ownership of 30% or more of either (x)
the then outstanding shares of common stock of the Company (the “Outstanding Common Stock”) or (y) the combined voting
power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding
Voting Securities”), provided that for purposes of this subsection (i), the following acquisitions shall not constitute
a Change of Control: (A) any acquisition directly from the Company, (B) any acquisition by the Company, (C) any acquisition by
any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company,
or (D) any acquisition by any corporation pursuant to a transaction which complies with clauses (A), (B) and (C) of subsection
(ii) hereof; or

 

    	 

    	 

    

 

(ii)consummation
after the Effective Date of a reorganization, merger or consolidation or sale or other disposition of all or substantially all
of the assets of the Company (a “Corporate Transaction”) in each case, unless, following such Corporate Transaction,
(A) (1) all or substantially all of the persons who were the beneficial owners of the Outstanding Common Stock immediately prior
to such Corporate Transaction beneficially own, directly or indirectly, more than 30% of the then outstanding shares of common
stock of the corporation resulting from such Corporate Transaction, and (2) all or substantially all of the persons who were the
beneficial owners of the Outstanding Voting Securities immediately prior to such Corporate Transaction beneficially own, directly
or indirectly, more than 30% of the combined voting power of the then outstanding voting securities entitled to vote generally
in the election of directors of the corporation resulting from such Corporate Transaction (including, without limitation, a corporation
which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly
or through one or more subsidiaries) in substantially the same proportions as their ownership of the Outstanding Common Stock and
the Outstanding Voting Securities immediately prior to such Corporate Transaction, as the case may be, (B) no Person (excluding
(1) any corporation resulting from such Corporate Transaction or any employee benefit plan (or related trust) of the Company or
such corporation resulting from such Corporate Transaction and (2) any Person approved by the members of the Board in office immediately
prior to such Corporate Transaction) beneficially owns, directly or indirectly, 30% or more of the then outstanding shares of common
stock of the corporation resulting from such Corporate Transaction or the combined voting power of the then outstanding voting
securities of such corporation except to the extent that such ownership existed prior to such Corporate Transaction and (C) at
least a majority of the members of the board of directors of the corporation resulting from such Corporate Transaction were members
of the Board at the time of the execution of the initial agreement or of the action of the Board providing for such Corporate Transaction.

 

(e)               
At any time during the Term of this Agreement, the Employee may terminate this Agreement by giving at least thirty
(30) days written notice to the Company of her intent to terminate this Agreement, with the date of termination to be specified
in such notice.

 

(f)               
If this Agreement is terminated by the Employee pursuant to Section 6(e) hereof, then the Company will have
no obligation to pay any amount to the Employee other than amounts earned or accrued pursuant to Section 3 hereof, but which
have not yet been paid, as of the date of termination.

 

7.             Assignment by Employee. Except as otherwise expressly provided herein, the Employee agrees for herself,
and on behalf of her executors and administrators, heirs, legatees, distributees and any other person or persons claiming any benefits
under her by virtue of this Agreement, that this Agreement and the rights, interests and benefits hereunder shall not be assigned,
transferred, pledged or hypothecated in any way by the Employee or any executor, administrator, heir, legatee, distributee or person
claiming under the Employee by virtue of this Agreement and shall not be subject to execution, attachment or similar process. Any
attempt at assignment, transfer, pledge or hypothecation or other disposition of this Agreement or of such rights, interests and
benefits contrary to the foregoing provision, or the levy of any attachment or similar process thereupon, shall be null and void
and without effect.

 

    	 

    	 

    

 

8.             Successors of the Company. This Agreement shall be binding on and inure to the benefit of any Successor
(as hereinafter defined) of the Company and any such Successor shall be deemed substituted for the Company under the terms of this
Agreement. As used in this Agreement, the term “Successor” shall include any person, firm, corporation or other
business entity which at any time, whether by merger, purchase or otherwise, acquires all or substantially all of the assets or
businesses of the Company; but no such substitution shall relieve such companies of their original obligations hereunder. This
Agreement may not otherwise be assigned by the Company without the Employee's consent to any person, firm, corporation, limited
liability company, trust or other entity.

 

9.             Notices. All notices or other communications that are required or may be given under this Agreement
shall be in writing and shall be deemed to have been duly given when delivered in person, transmitted by telecopier or mailed by
registered or certified first class mail, postage prepaid, return receipt requested, to the parties hereto at the address set forth
below (as the same may be changed from time to time by notice similarly given) or the last known business or residence address
of such other person as may be designated by either party hereto in writing.

 

If to the Company:

Repros Therapeutics Inc.

2408 Timberloch Place, Suite B-7

The Woodlands, Texas 77380

Attn: Joseph S. Podolski

 

If to the Employee:

Jaye Thompson, PhD

58 N Brokenfern Drive

The Woodlands, Texas 77380

 

 

10.           Waiver of Breach. A waiver by the Company or the Employee of a breach of any provision of this Agreement
by the other party shall not operate or be construed as a waiver of any other breach by the other party.

 

11.           Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
State of Texas.

 

12.           Severability. If any provision of this Agreement shall, for any reason, be held to violate any applicable
law, and so much of said Agreement is held to be unenforceable, then the invalidity of such specific provision herein shall not
be held to invalidate any other provision herein which shall remain in full force and effect.

 

13.           Amendment. This Agreement constitutes and contains the entire agreement of the parties and supersedes
any and all prior negotiations, correspondence, understandings and agreements between the parties respecting the subject matter
hereof. This Agreement may be modified only by an agreement in writing executed by all the parties hereto.

 

14.           Headings. The section and subsection headings contained in this Agreement are for reference purposes
only and shall not affect in any way the meaning or interpretation of this Agreement.

 

    	 

    	 

    

 

15.           Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be
deemed an original, and all of which together shall constitute one instrument.

 

16.           Cumulative Remedies. All rights and remedies hereunder are cumulative and are in addition to all other
rights and remedies provided by law, agreement or otherwise.

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as of the date first written above.

 

 

	 	COMPANY:
	 	 
	 	REPROS THERAPEUTICS INC.
	 	 
	 	 
	 	By: /s/ Joseph S. Podolski                                     
	 	       Joseph S. Podolski, President and CEO
	 	 
	 	 
	 	EMPLOYEE:
	 	 
	 	 
	 	By: /s/ Jaye Thompson                                          
	 	       Jaye Thompson, PhD

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]